Prognosis
Pfizer and BioNTech to Get $3.2 Billion From US in Covid Vaccine Deal
Syringes of the Pfizer-BioNTech Covid-19 vaccine.
Photographer: Scotty Perry/BloombergThis article is for subscribers only.
The US agreed to pay vaccine partners Pfizer Inc. and BioNTech SE $3.2 billion in a deal for 105 million of their messenger RNA shots against Covid-19.
The deal is for doses for adults, children and infants, and may include some shots that target the omicron variant, according to a statement from the companies. Deliveries are planned to begin as soon as late summer and continue into the fourth quarter. Payment will occur after the supply is delivered.